This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wattenberg, E. V. Articles by Rosner, M. R. Search for Related Content PubMed PubMed Citation Articles by Wattenberg, E. V. Articles by Rosner, M. R.

Heterologous Regulation of the Epidermal Growth Factor Receptor by Palytoxin, a Non-12-O-Tetradecanoylphorbol-13-acetate-type Tumor Promoter¹

Department of Applied Biological Sciences, Massachusetts Institute of Technology, Cambridge, Massachusetts [E. V. W., M. R. R.], and Cancer Prevention Division, National Cancer Center Research Institute, Chuo-ku, Tokyo 104, Japan [H. F.]

Previous results have established that 12-O-tetradecanoylphorbol-13-acetate (TPA)-type tumor promoters can alter the properties of the epidermal growth factor (EGF) receptor through activation of protein kinase C. In order to determine whether other, non-TPA-type tumor promoters might similarly influence growth-mediating receptors, we investigated the effect of palytoxin on EGF binding in Swiss 3T3 fibroblasts and human epidermal carcinoma (A431) cells. In both cell types, pretreatment with a low dose of palytoxin (1–11 pM) at 37°C causes a decrease in EGF binding. In Swiss 3T3 cells the inhibitory effect is temperature dependent and does not occur at 4°C, indicating that palytoxin is not directly competing with EGF for binding. As assessed by effects on DNA synthesis, palytoxin is not toxic at these concentrations and does not appear to be mitogenic for these cells. Although palytoxin, like phorbol esters, alters EGF binding, its action in Swiss 3T3 cells differs from that of TPA-type tumor promoters in at least 4 respects: (a) the kinetics and dose dependence differ significantly from that of phorbol dibutyrate; (b) the effect is not readily reversible; (c) there is loss of low-affinity as well as high-affinity binding sites; (d) the effect is independent of cellular protein kinase C levels. These results indicate that palytoxin is capable of heterologous regulation of the EGF receptor through a novel mechanism and suggest that certain non-TPA-type tumor promoters as well as TPA-type tumor promoters may act in part through modulation of growth regulatory pathways.

¹ Supported by National Cancer Institute Awards CA35541 and CA40407 to M. R. R. and National Institute of Health Toxicology Grant T32-E507020 to E. V. W.

² To whom requests for reprints should be addressed. Present address: University of Chicago, Ben May Laboratory for Cancer Research, 5841 S. Maryland Ave., Chicago, IL 60637.

Received 2/ 9/87. Revised 5/26/87. Accepted 6/ 9/87.

This article has been cited by other articles:

				E. V. Wattenberg Palytoxin: exploiting a novel skin tumor promoter to explore signal transduction and carcinogenesis Am J Physiol Cell Physiol, January 1, 2007; 292(1): C24 - C32. [Abstract] [Full Text] [PDF]

				J. K. Warmka, L. J. Mauro, and E. V. Wattenberg Mitogen-activated Protein Kinase Phosphatase-3 Is a Tumor Promoter Target in Initiated Cells That Express Oncogenic Ras J. Biol. Chem., August 6, 2004; 279(32): 33085 - 33092. [Abstract] [Full Text] [PDF]

				M. S. Iordanov and B. E. Magun Loss of Cellular K+ Mimics Ribotoxic Stress. INHIBITION OF PROTEIN SYNTHESIS AND ACTIVATION OF THE STRESS KINASES SEK1/MKK4, STRESS-ACTIVATED PROTEIN KINASE/c-Jun NH2-TERMINAL KINASE 1, AND p38/HOG1 BY PALYTOXIN J. Biol. Chem., February 6, 1998; 273(6): 3528 - 3534. [Abstract] [Full Text] [PDF]

				D. W. Kuroki, A. Minden, I. Sanchez, and E. V. Wattenberg Regulation of a c-Jun Amino-terminal Kinase/Stress-activated Protein Kinase Cascade by a Sodium-dependent Signal Transduction Pathway J. Biol. Chem., September 19, 1997; 272(38): 23905 - 23911. [Abstract] [Full Text] [PDF]